title: Comparative safety of antipsychotic medications in nursing home residents.
abstract: OBJECTIVE
  To compare the risk of major medical events in nursing home residents newly initiated on conventional or atypical antipsychotic medications (APMs).
  
  
  METHODS
  Cohort study, using linked Medicaid, Medicare, Minimum Data Set, and Online Survey Certification and Reporting data. Propensity score-adjusted proportional hazards models were used to compare risks for medical events at a class and individual drug level.
  
  
  METHODS
  Nursing homes in 45 U.S. states.
  
  
  METHODS
  Eighty-three thousand nine hundred fifty-nine Medicaid-eligible residents aged 65 and older who initiated APM treatment after nursing home admission in 2001 to 2005.
  
  
  METHODS
  Hospitalization for myocardial infarction, cerebrovascular events, serious bacterial infections, and hip fracture within 180 days of treatment initiation.
  
  
  RESULTS
  Risks of bacterial infections (hazard ratio (HR) = 1.25, 95% confidence interval (CI) = 1.05-1.49) and possibly myocardial infarction (HR = 1.23, 95% CI = 0.81-1.86) and hip fracture (HR = 1.29, 95% CI = 0.95-1.76) were higher, and risks of cerebrovascular events (HR = 0.82, 95% CI = 0.65-1.02) were lower in participants initiating conventional APMs than in those initiating atypical APMs. Little variation existed between individual atypical APMs, except for a somewhat lower risk of cerebrovascular events with olanzapine (HR = 0.91, 95% CI = 0.81-1.02) and quetiapine (HR = 0.89, 95% CI = 0.79-1.02) and a lower risk of bacterial infections (HR = 0.83, 95% CI = 0.73-0.94) and possibly a higher risk of hip fracture (HR = 1.17, 95% CI = 0.96-1.43) with quetiapine than with risperidone. Dose-response relationships were observed for all events (HR = 1.12, 95% CI = 1.05-1.19 for high vs low dose for all events combined).
  
  
  CONCLUSIONS
  These associations underscore the importance of carefully selecting the specific APM and dose and monitoring their safety, especially in nursing home residents who have an array of medical illnesses and are undergoing complex medication regimens.
authors.affiliation: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02120, USA. khuybrechts@partners.org
authors.forename: Krista F
authors.initials: KF
authors.lastname: Huybrechts
authors.forename: Sebastian
authors.initials: S
authors.lastname: Schneeweiss
authors.forename: Tobias
authors.initials: T
authors.lastname: Gerhard
authors.forename: Mark
authors.initials: M
authors.lastname: Olfson
authors.forename: Jerry
authors.initials: J
authors.lastname: Avorn
authors.forename: Raisa
authors.initials: R
authors.lastname: Levin
authors.forename: Judith A
authors.initials: JA
authors.lastname: Lucas
authors.forename: Stephen
authors.initials: S
authors.lastname: Crystal
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D014150:Antipsychotic Agents / Q000009:adverse effects*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008297:Male; D008484:Medicaid; D006278:Medicare; D009735:Nursing Homes; D061214:Patient Safety; D016016:Proportional Hazards Models; D018570:Risk Assessment; D012307:Risk Factors; D014481:United States
chemical_list: D014150:Antipsychotic Agents